Keywords: Insomnia; Almorexant; Orexin; Efficacy; Zolpidem; AEs; adverse events; BMI; body mass index; CI; confidence intervals; CNS; central nervous system; dWRT; delayed Word Recall Test; DSST; Digit Symbol Substitution Test; DORA; dual OX1R and OX2R antagonist;